Cargando…
Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
BACKGROUND: Around 30% of patients with schizophrenia are considered treatment resistant (TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable antipsychotics could be a useful augmentation strategy for nonresponders. METHODS: We conducted a multicenter, observational, n...
Autores principales: | Bioque, Miquel, Parellada, Eduard, García-Rizo, Clemente, Amoretti, Sílvia, Fortea, Adriana, Oriolo, Giovanni, Palau, Pol, Boix-Quintana, Ester, Safont, Gemma, Bernardo, Miquel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443780/ https://www.ncbi.nlm.nih.gov/pubmed/32669145 http://dx.doi.org/10.1192/j.eurpsy.2020.72 |
Ejemplares similares
-
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
por: González-Rodríguez, Alexandre, et al.
Publicado: (2015) -
M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA
por: Amoretti, Silvia, et al.
Publicado: (2020) -
Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022) -
The role of genetics in cognitive remediation in schizophrenia: A systematic review
por: Penadés, Rafael, et al.
Publicado: (2019) -
Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)